Human Growth Hormone Injections in the Knee Joint to Treat Osteoarthritis
Public ClinicalTrials.gov record NCT06354023. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Administration of Recombinant Human Growth Hormone in the Knee Joint of Patients Suffering from Osteoarthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if growth hormone injections can be used to treat osteoarthritis (OA) in the knee. Human studies have shown that repeated injections of human growth hormone leads to the production of articular chondrocytes, which are the cells that make up the cartilage in the knee joint. Restoring cartilage in the knee can alleviate pain, improve function, and postpone the need for a joint replacement procedure. The main questions the study aims to answer are: * Do growth hormone injections in the knee joint stimulate cartilage growth? * Do the injections lower pain and stiffness in the participant's treated knee? * Does the participant have more mobility after the injections? The physician will monitor the participant's progress through X-ray images, questionnaires, and physical evaluation of the treated knee. For the trial, participants will: * Receive a growth hormone injection in their knee once per week for six weeks, for a total of 6 injections. * Complete at-home exercises during the treatment period. * Use crutches as needed during the trial. * Have X-rays taken at 8 weeks, 6 months, and 12 months after the first injection. * Go to follow-up visits at 8 weeks, 6 months, and 12 months after the first injection. * Complete treatment surveys before treatment starts and after it is finished.
Study identification
- NCT ID
- NCT06354023
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 72 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2025
- Primary completion
- Feb 7, 2026
- Completion
- Feb 7, 2026
- Last update posted
- Oct 3, 2024
2025 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| BioShift Life Sciences | Santa Monica | California | 90404 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06354023, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2024 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06354023 live on ClinicalTrials.gov.